Baloxavir Marboxil is named as a drug or biological intervention in 5 clinical trials in our India, China, Ireland and USA trial registers, 3 of which are recruiting. Lead sponsors include UMC Utrecht (1), Hoffmann-La Roche (1) and University of Oxford (1). Registered phases: Phase 3, Observational and Not applicable. Conditions studied include Influenza; Community-acquired Pneumonia, Influenza, COVID-19; Pneumonia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT02735707 | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Community-acquired Pneumonia, Influenza, COVID-19 |
Phase 3 | Recruiting |
| NCT04381936 | Randomised Evaluation of COVID-19 Therapy (ClinicalTrials.gov ↗) Pneumonia |
Phase 3 | Recruiting |
| NCT06094010 | A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts (ClinicalTrials.gov ↗) Influenza |
Phase 3 | Recruiting |
| NCT07393685 | Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD (ClinicalTrials.gov ↗) Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases |
Observational | Not yet open |
| NCT06762587 | Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting (ClinicalTrials.gov ↗) Influenza, Influenza Prophylaxis, Nosocomial Infection |
Not applicable | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Influenza | 2 |
| Community-acquired Pneumonia, Influenza, COVID-19 | 1 |
| Pneumonia | 1 |
| Acute Exacerbation of Chronic Obstructive Pulmonary Disease | 1 |
| Influenza, Human | 1 |
| Virus Diseases | 1 |
| Influenza Prophylaxis | 1 |
| Nosocomial Infection | 1 |
| Lead sponsor | Trials |
|---|---|
| UMC Utrecht | 1 |
| Hoffmann-La Roche | 1 |
| University of Oxford | 1 |
| Tianjin Medical University | 1 |
| Capital Medical University | 1 |
| Register | Baloxavir Marboxil trials |
|---|---|
| Clinical trials in India | 2 |
| Clinical trials in China | 2 |
| Clinical trials in Ireland | 1 |
| Clinical trials in USA | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Baloxavir Marboxil works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Baloxavir Marboxil (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.